Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on

    A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on

    FromThe BioWorld Insider Podcast

    Start listeningView podcast show

    A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on

    FromThe BioWorld Insider Podcast

    ratings:
    Length:
    31 minutes
    Released:
    Aug 20, 2021
    Format:
    Podcast episode

    Description

    Though Revolution Medicines Inc.’s RAS companion / SHP2 inhibitor RMC-4630 failed to show efficacy in two early-stage combination trials, the company is moving forward with the candidate, its lead asset, partnered with Sanofi SA. Mark Goldsmith, Revolution’s president, CEO and chairman joined the BioWorld Insider Podcast to discuss the challenges and progress in other experiments. Hosted on Acast. See acast.com/privacy for more information.
    Released:
    Aug 20, 2021
    Format:
    Podcast episode

    Titles in the series (38)

    Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation. Hosted on Acast. See acast.com/privacy for more information.